Case Report of a Kidney Transplant Recipient Converted to Everolimus Due to Malignancy: Resolution of Bronchiolitis Obliterans Organizing Pneumonia Without Everolimus Discontinuation

Transplantation Proceedings

Volumn 39, Issue 3, 2007, Pages 594-595

  Carreño, C Agost ^a   Gadea, M ^a  

^a Hospital Aeronautico Central   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE; STEROID;

ADULT; ARTICLE; BIOPSY; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER REGRESSION; CASE REPORT; COUGHING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FIBEROPTIC BRONCHOSCOPY; GRAFT RECIPIENT; GYNECOLOGIC CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY GRAFT; LIVING DONOR; LUNG; PRIORITY JOURNAL; THORAX RADIOGRAPHY; VAGINA DISEASE; WART VIRUS;

ADRENAL CORTEX HORMONES; AZATHIOPRINE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CYCLOSPORINE; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; METHYLPREDNISOLONE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYCYSTIC KIDNEY DISEASES; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; VAGINAL NEOPLASMS;

EID: 34147165950     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.12.023     Document Type: Article

References (10)

1. Agrahakar M.L., Cinclair R.D., Kuo Y.F., et al. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 66 (2004) 383
2. Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 56 (2005) 71
3. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
4. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1517
5. Nuovo G.J. The role of human papillomavirus in gynecological diseases. Crit Rev Clin Lab Sci 37 (2000) 183
6. Yee K.W., Zeng Z.X., Knopleva M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12 (2006) 5165
7. Lane H.A., and Lebwol D. Future directions in the treatment of hormone sensitive advanced breast cancer: the RAD 001 (everolimus)-letrozole clinical program. Semin Oncol 33 (2006) S18
8. Khariwala S.S., Kjaergaard J., Lorenz R., et al. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 116 (2006) 814
9. Lebbé C., Euvrard S., Barreu B., et al. Sirolimus conversion for patients with Kaposi sarcoma. Am J Transplant 6 (2006) 2164
10. Haydar A.A., Denton M., West A., et al. Sirolimus induced pneumonitis: three cases and a review of the literature. Am J Transplant 4 (2004) 137